Value of plasma miR-193a-5p level on diagnosis and treatment evaluation in acute myeloid leukemia
10.3760/cma.j.issn.1009-9921.2016.06.007
- VernacularTitle:血浆miR-193a-5p在急性髓系白血病诊疗评估中的价值
- Author:
Na ZHANG
;
Zhifang XU
;
Fanggang REN
;
Junxia ZHAO
;
Jing XU
;
Xiuhua CHEN
;
Yanhong TAN
;
Jianmei CHANG
;
Feng XUE
;
Feng GAO
;
Jie PAN
;
Bin YIN
;
Hongwei WANG
- Publication Type:Journal Article
- Keywords:
Leukemia,myeloid,acute;
miR-193a-5p;
Polymerase chain reaction
- From:
Journal of Leukemia & Lymphoma
2016;25(6):349-353
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the value of the plasma miR-193a-5p level on diagnosis and monitoring the response to treatment in acute myeloid leukemia (AML). Methods Peripheral blood samples were obtained from AML patients enrolled in hematology department of the Second Hospital of Shanxi Medical University from July 2015 to December 2015, including 30 de novo AML patients, 9 patients in complete remission (CR) and 6 patients in relapse. Peripheral blood samples from 15 healthy people were randomly choosed as the health control group. Plasma miR-193a-5p expression levels were detected by using quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). Results The plasma miR-193a-5p relative expression level of AML patients group [0.465 6 (0.103 1-5.000 2)] was obviously lower than that of health control group [0.766 1 (0.052 1-3.134 4)] (U= 122, P= 0.018 7). The plasma miR-193a-5p relative expression levels of de novo group and relapse AML group were significantly lower than those of CR group and health control group (P<0.05), and there was no significant difference between the CR group and health control group (U= 56, P= 0.511 9). No significant correlation was found between the plasma miR-193a-5p level and age, gender, blast percentage of the bone marrow, peripheral blood leukocyte count, platelet count, CD34+cells'percentage and so on. Conclusion The decreased plasma miR-193a-5p expression level can be served as a new and noninvasive biomarker for the evaluation of diagnosis and treatment in AML.
